276 related articles for article (PubMed ID: 24261839)
1. Estimate of the global burden of cervical adenocarcinoma and potential impact of prophylactic human papillomavirus vaccination.
Pimenta JM; Galindo C; Jenkins D; Taylor SM
BMC Cancer; 2013 Nov; 13():553. PubMed ID: 24261839
[TBL] [Abstract][Full Text] [Related]
2. Cervical adenocarcinoma: moving towards better prevention.
Seoud M; Tjalma WA; Ronsse V
Vaccine; 2011 Nov; 29(49):9148-58. PubMed ID: 21983356
[TBL] [Abstract][Full Text] [Related]
3. Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020-99: a modelling study.
Simms KT; Steinberg J; Caruana M; Smith MA; Lew JB; Soerjomataram I; Castle PE; Bray F; Canfell K
Lancet Oncol; 2019 Mar; 20(3):394-407. PubMed ID: 30795950
[TBL] [Abstract][Full Text] [Related]
4. Estimation of the potential overall impact of human papillomavirus vaccination on cervical cancer cases and deaths.
Van Kriekinge G; Castellsagué X; Cibula D; Demarteau N
Vaccine; 2014 Feb; 32(6):733-9. PubMed ID: 24291200
[TBL] [Abstract][Full Text] [Related]
5. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study.
de Sanjose S; Quint WG; Alemany L; Geraets DT; Klaustermeier JE; Lloveras B; Tous S; Felix A; Bravo LE; Shin HR; Vallejos CS; de Ruiz PA; Lima MA; Guimera N; Clavero O; Alejo M; Llombart-Bosch A; Cheng-Yang C; Tatti SA; Kasamatsu E; Iljazovic E; Odida M; Prado R; Seoud M; Grce M; Usubutun A; Jain A; Suarez GA; Lombardi LE; Banjo A; Menéndez C; Domingo EJ; Velasco J; Nessa A; Chichareon SC; Qiao YL; Lerma E; Garland SM; Sasagawa T; Ferrera A; Hammouda D; Mariani L; Pelayo A; Steiner I; Oliva E; Meijer CJ; Al-Jassar WF; Cruz E; Wright TC; Puras A; Llave CL; Tzardi M; Agorastos T; Garcia-Barriola V; Clavel C; Ordi J; Andújar M; Castellsagué X; Sánchez GI; Nowakowski AM; Bornstein J; Muñoz N; Bosch FX;
Lancet Oncol; 2010 Nov; 11(11):1048-56. PubMed ID: 20952254
[TBL] [Abstract][Full Text] [Related]
6. Human papillomavirus type-distribution in the cervix of Chinese women: a meta-analysis.
Bao YP; Li N; Smith JS; Qiao YL
Int J STD AIDS; 2008 Feb; 19(2):106-11. PubMed ID: 18334063
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
Aguilar IB; Mendoza LO; García O; Díaz I; Figueroa J; Duarte RM; Perdomo G; Garcia AG; Janusz CB
Vaccine; 2015 May; 33 Suppl 1():A167-73. PubMed ID: 25919157
[TBL] [Abstract][Full Text] [Related]
8. Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries.
Brisson M; Kim JJ; Canfell K; Drolet M; Gingras G; Burger EA; Martin D; Simms KT; Bénard É; Boily MC; Sy S; Regan C; Keane A; Caruana M; Nguyen DTN; Smith MA; Laprise JF; Jit M; Alary M; Bray F; Fidarova E; Elsheikh F; Bloem PJN; Broutet N; Hutubessy R
Lancet; 2020 Feb; 395(10224):575-590. PubMed ID: 32007141
[TBL] [Abstract][Full Text] [Related]
9. Human papillomavirus: current status and issues of vaccination.
Malik H; Khan FH; Ahsan H
Arch Virol; 2014 Feb; 159(2):199-205. PubMed ID: 24022639
[TBL] [Abstract][Full Text] [Related]
10. Burden of disease associated with cervical cancer in malaysia and potential costs and consequences of HPV vaccination.
Aljunid S; Zafar A; Saperi S; Amrizal M
Asian Pac J Cancer Prev; 2010; 11(6):1551-9. PubMed ID: 21338196
[TBL] [Abstract][Full Text] [Related]
11. Evidence-based impact projections of single-dose human papillomavirus vaccination in India: a modelling study.
Man I; Georges D; de Carvalho TM; Ray Saraswati L; Bhandari P; Kataria I; Siddiqui M; Muwonge R; Lucas E; Berkhof J; Sankaranarayanan R; Bogaards JA; Basu P; Baussano I
Lancet Oncol; 2022 Nov; 23(11):1419-1429. PubMed ID: 36174583
[TBL] [Abstract][Full Text] [Related]
12. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Central and Eastern Europe.
Poljak M; Seme K; Maver PJ; Kocjan BJ; Cuschieri KS; Rogovskaya SI; Arbyn M; Syrjänen S
Vaccine; 2013 Dec; 31 Suppl 7():H59-70. PubMed ID: 24332298
[TBL] [Abstract][Full Text] [Related]
13. Burden of Human papillomavirus (HPV)-related disease and potential impact of HPV vaccines in the Republic of Korea.
Kim YT; Serrano B; Lee JK; Lee H; Lee SW; Freeman C; Oh JK; Alemany L; Bosch FX; Bruni L
Papillomavirus Res; 2019 Jun; 7():26-42. PubMed ID: 30599280
[TBL] [Abstract][Full Text] [Related]
14. The impact of anti HPV vaccination on cervical cancer incidence and HPV induced cervical lesions: consequences for clinical management.
Brinkman JA; Caffrey AS; Muderspach LI; Roman LD; Kast WM
Eur J Gynaecol Oncol; 2005; 26(2):129-42. PubMed ID: 15857016
[TBL] [Abstract][Full Text] [Related]
15. A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine.
Goldie SJ; Grima D; Kohli M; Wright TC; Weinstein M; Franco E
Int J Cancer; 2003 Oct; 106(6):896-904. PubMed ID: 12918067
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of vaccination against HPV infections to prevent cervical cancer in France: present assessment and pathways to improve vaccination policies.
Ribassin-Majed L; Lounes R; Clémençon S
PLoS One; 2012; 7(3):e32251. PubMed ID: 22427828
[TBL] [Abstract][Full Text] [Related]
17. Distribution of HPV types associated with cervical cancers in Scotland and implications for the impact of HPV vaccines.
Cuschieri K; Brewster DH; Williams AR; Millan D; Murray G; Nicoll S; Imrie J; Hardie A; Graham C; Cubie HA
Br J Cancer; 2010 Mar; 102(5):930-2. PubMed ID: 20145611
[TBL] [Abstract][Full Text] [Related]
18. Human papilloma virus (HPV) prophylactic vaccination: challenges for public health and implications for screening.
Adams M; Jasani B; Fiander A
Vaccine; 2007 Apr; 25(16):3007-13. PubMed ID: 17292517
[TBL] [Abstract][Full Text] [Related]
19. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention.
Castellsagué X; Díaz M; de Sanjosé S; Muñoz N; Herrero R; Franceschi S; Peeling RW; Ashley R; Smith JS; Snijders PJ; Meijer CJ; Bosch FX;
J Natl Cancer Inst; 2006 Mar; 98(5):303-15. PubMed ID: 16507827
[TBL] [Abstract][Full Text] [Related]
20. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Russian Federation, the Western countries of the former Soviet Union, Caucasus region and Central Asia.
Rogovskaya SI; Shabalova IP; Mikheeva IV; Minkina GN; Podzolkova NM; Shipulina OY; Sultanov SN; Kosenko IA; Brotons M; Buttmann N; Dartell M; Arbyn M; Syrjänen S; Poljak M
Vaccine; 2013 Dec; 31 Suppl 7():H46-58. PubMed ID: 24332297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
